



Mylan N.V.
Investor Relations Department
PO Box 2648
Portland, OR 97208-2648
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: MYL

Last Trade:	31.39
Trade Time:	4:00 PM ET Sep 20, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	29.39 - 45.87
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 7,500 marketed products around the world, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS in the developing world depend. We... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Sep 14, 2017

[Mylan Expands Women's Healthcare Portfolio with Launch of Generic Minastrin® 24 FE Tablets](#)

Sep 13, 2017

[Mylan Names Dennis Zeleny as Chief Human Relations Officer](#)

Aug 24, 2017

[Otsuka and Mylan Announce License Agreement to Commercialize Delamanid \(Delyba™\) for Multidrug-Resistant Tuberculosis \(MDR-TB\) in High-Burden Countries](#)

Aug 17, 2017

[Mylan Finalizes Settlement Agreement on Medicaid Rebate Classification for EpiPen® Auto-Injector](#)

Aug 10, 2017

[Mylan Advances Access in the Fight Against HIV with the Launch of Three Generic Antiretroviral Medicines in Canada](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

May 23, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 9, 2017

[Quarterly Report \(10-Q\)](#)

May 10, 2017

[Quarterly Report \(10-Q\)](#)